ArticleEuropean radiology2025
Beyond nodules: body composition as a biomarker for future lung cancer.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Risk prediction for lung cancer screening: a systematic review and meta-regression.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
Corrections and comments
- Commented on by
- Update of
Authors and funding
8 authors.
Funding
Abstract
objectivesTo investigate if body composition can serve as a biomarker for assessing the risk of developing lung cancer. MATERIALS AND
methodsWe conducted a retrospective study using low-dose computed tomography (LDCT) scans from the Pittsburgh lung screening study (PLuSS) (n = 3635, 22 follow-up years) and the NLST-ACRIN (n = 16,360, 8 follow-up years) cohort. Five types of body tissues, including subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), intramuscular adipose tissue (IMAT), skeletal muscle (SM), and bone, were automatically segmented by our previously developed algorithms. Volume and density metrics were computed. Cause-specific Cox proportional hazards models were utilized to assess hazard ratios (HRs). Time-dependent area under the receiver operating characteristic curve (AUC-ROC) was used to evaluate model performance. The cumulative incidence function was estimated for different risk groups.
resultsThe final composite models were formed by age (HR = 1.30 (95% CI: 1.17-1.43)), current smoking status (HR = 1.85 (1.49-2.28)), bone volume (HR = 1.38 (1.25-1.52)), bone density (HR = 0.80 (0.71-0.89)), SM density (HR = 0.62 (0.58-0.66)), IMAT ratio (HR = 0.65 (0.58-0.73)), and SAT volume (HR = 0.76 (0.67-0.87)). The model trained on the PLuSS cohort achieved a mean AUC of 0.77 (0.75-0.79) over 21 years and 0.71 (0.68-0.74) over the first 7 years for lung cancer prediction. External validation on the NLST cohort yielded AUC values ranging from 0.63 to 0.66 over a 7-year follow-up period. The model trained on a combined dataset of PLuSS and NLST achieved a mean AUC of 0.71 (0.7-0.72) over 21 years.
conclusionThree-dimensional body composition metrics assessed through LDCT are a significant predictor of lung cancer risk. KEY POINTS: Question Is body composition a biomarker for lung cancer risk assessment? Findings Body composition metrics derived from low-dose CT scans, including volumes and densities of fat, bone, and muscle, are strong predictors of lung cancer risk. Clinical relevance Lung cancer risk stratification can be improved by body composition features, providing guidance for personalized lung cancer screening strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.